The government announced today that the National Board of Health and Welfare will be commissioned to pay SEK 16.5 million to GMS to pilots in genetic and molecular diagnostics. Of this, SEK 8.5 million will go to pilot projects that deal with childhood cancer and the remaining 8 million to pilot projects focusing on breast cancer and ovarian cancer.
– We are very happy about the government’s targeted investment in new diagnostics for childhood cancer and cancer that affects women. This is an important piece of the puzzle in Sweden’s investment and ambition to be an international leader in the transition to precision medicine, says Richard Rosenquist Brandell, chairman of GMS ‘management group.
Pressrelease from Ministry of Health and Social Affairs (in Swedish)
